Last reviewed · How we verify
NCT07192705
Health Impact of Non-Tuberculous Mycobacteria Pulmonary Disease (NTM-PD)
trial in Non-Tuberculous Mycobacteria Pulmonary Disease in 80 participants. Currently enrolling.
2 February 2026
Quick facts
| Lead sponsor | University College, London |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 14 August 2025 |
| Primary completion | 2 February 2026 |
| Estimated completion | 1 June 2026 |
| Sites | 1 location across United Kingdom |
Conditions studied
- Non-Tuberculous Mycobacteria Pulmonary Disease — all drugs for Non-Tuberculous Mycobacteria Pulmonary Disease →
- Bronchiectasis — all drugs for Bronchiectasis →
Sponsor
University College, London
Who can join
18 and older, any sex, with Non-Tuberculous Mycobacteria Pulmonary Disease or Bronchiectasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Nontuberculous mycobacteria (NTM) are environmental organisms found in soil and water. The majority do not cause human disease. When they do, this is mostly as a chronic lung infection in people with long-term lung problems such as chronic obstructive pulmonary disease (COPD), bronchiectasis, or cystic fibrosis. The number of people with NTM pulmonary disease (PD) is increasing, and its management can be complex, requiring prolonged treatment with multiple, often toxic, drugs in someone who may already be frail. Non-drug approaches, such as airway clearance techniques, structured exercise, nutritional support and psychological care are used to help manage bronchiectasis and COPD. However, there is limited evidence about their benefit in people with NTM-PD. Also, it is not clear whether these patients' health needs are different from people with bronchiectasis alone. The investigators want to identify the most important symptoms encountered by people with NTM-PD and patient preferences for care. The study also aims to explore whether the need for non-drug measures differs between people with and without NTM-PD who have other underlying lung disease. The research will take place at one NHS centre and involve a single assessment of 40 people with NTM-PD not using specific antibiotics to treat their NTM and 40 people with bronchiectasis but no evidence for NTM. Following consent, and mainly using questionnaires, participants will be asked about their physical and mental health, and nutritional status. Exercise capacity, muscle strength and body muscle/fat composition will also be assessed using simple tests. The total time required will be a maximum of one hour. Recruitment to the study will last around six months. The results will help improve understanding of specific needs of people with NTM-PD and guide clinically relevant research in this area.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07192705
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University College, London trials
Trials by the same sponsor.
- NCT07386652 — Intensive Comprehensive Aphasia Programme for People With Post-Stroke Aphasia · NA · not yet recruiting
- NCT06924086 — The Children's Adaptive Deep Brain Stimulation for Epilepsy Trial · NA · recruiting
- NCT07386678 — Study of Imaging and Molecular Biomarkers in Uncomplicated Rhegmatogenous Retinal Detachment · not yet recruiting
- NCT07414940 — ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium · Phase 1, PHASE2 · not yet recruiting
- NCT07214454 — TCDS for the Treatment of Chronic Migraine · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07192705 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University College, London
- Last refreshed: 25 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07192705.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing